1. Academic Validation
  2. Nitric Oxide-Responsive Degradable Drug-Loaded Liposomal Nanomotors for the Treatment of Peritoneal Metastases Cancer

Nitric Oxide-Responsive Degradable Drug-Loaded Liposomal Nanomotors for the Treatment of Peritoneal Metastases Cancer

  • ACS Appl Mater Interfaces. 2025 Jun 11;17(23):33357-33369. doi: 10.1021/acsami.5c01299.
Yao Zhang 1 Wenjun Dai 1 Zhengwei Chen 1 Yawen Wu 1 Jiawei Li 2 Chun Mao 1 Mimi Wan 1 Ke Zhang 2
Affiliations

Affiliations

  • 1 National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China.
  • 2 Department of Radiation Oncology, Hangzhou Cancer Institution, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Abstract

As a drug delivery vehicle, liposomes still have problems such as lack of targeting, difficulty in achieving effective tumor tissue penetration, and cellular internalization. Based on this, the drug-loaded Liposome nanomotors with liposomes that can respond to NO degradation as carriers and loaded with Anticancer drug DOX were designed for the treatment of peritoneal metastases Cancer (arginine-functionalized-DSPE@NO-responsive-lipids-DOX, l-Arg@Lip-DOX). The drug-loaded liposomal nanomotors have the ability to move toward tumors at high concentrations of ROS/iNOS, thereby achieving deep penetration and effective cellular internalization of tumor tissues. In addition, the guanidine group on the nanomotors can react with ROS/iNOS highly expressed in the tumor microenvironment to produce NO, which promotes the degradation of drug-loaded liposomal nanomotors and the rapid release of Anticancer drug DOX. Further in vitro and in vivo experiments confirmed that the nanomotors can achieve good therapeutic effects, providing a design idea for the treatment of peritoneal metastases and providing a promising candidate material for the delivery system of Cancer treatment drugs.

Keywords

chemotactic; liposome; nanomotor; nitric oxide; peritoneal metastatic cancer.

Figures
Products